You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 3.2% | 3.3% |
| Div Cover | 1.1 | 2.5 |
| Op Mrgn | 18.3% | 37.0% |
| ROCE | 39.3% |
| Latest | Forecast | |
|---|---|---|
| P/E | 28.1 | 1,147.9 |
| PEG | -1.0 | 0.1 |
| Price / Revenue | 4.1 | 3.8 |
| Price / Book value | 7.8 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 2.5% | 1.8% |
| PBT | -23.3% | n/a |
| EPS | -27.3% | 7.1% |
| DPS | 9.7% | 1.7% |
| Year Ending | Revenue (€m) |
Pre-tax (€m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | 39,807.00 | 4,659.00 | €1.42 | 39.4 | 5.1 | 8% | €1.85 | 3.3% |
| 2017-12-31 | 40,122.00 | 6,521.00 | $0.88 | 63.9 | -1.3 | -48% | $1.89 | 3.4% |
| 2018-12-31 | 42,294.00 | 8,701.00 | $2.34 | 32.2 | 0.2 | 166% | $1.99 | 2.6% |
| 2019-12-31 | 46,840.00 | 11,464.00 | $3.84 | 23.7 | 0.4 | 64% | $2.26 | 2.5% |
| 2020-12-31 | 47,994.00 | 8,791.00 | $2.79 | 29.3 | -1.1 | -27% | $2.48 | 3.0% |
| Merck to buy Pandion Therapeutics for $1.85bn Sharecast News | 25 Feb |
|---|---|
| AstraZeneca's breast cancer drug moves to early primary analysis Sharecast News | 17 Feb |
| AstraZeneca's Lynparza cancer drug approved by Japan Sharecast News | 29 Dec |